provides services such as haematology diagnostics, providing reagents and instruments for blood testing. It also offers immunoassay and clinical chemistry solutions for hospitals, labs, and diagnostic centres. Transasia operates haematology reagent filling lines, with a daily capacity of 30,000 liters and a production capability of 6,000 instruments per month. The company focuses on R&D and innovation to develop innovative diagnostic solutions for various diseases.

<table><thead><tr><th></th><th>Unit</th><th>FY23</th><th>FY24</th></tr></thead><tbody><tr><td>Revenue</td><td>Rs. Million</td><td>14,456</td><td>-</td></tr><tr><td>Revenue Growth</td><td>%</td><td>-</td><td>-</td></tr><tr><td>Operating Profit</td><td>Rs. Million</td><td>383</td><td>-</td></tr><tr><td>Operating Margins</td><td>%</td><td>3%</td><td>-</td></tr><tr><td>PAT</td><td>Rs Million</td><td>-872</td><td>-</td></tr><tr><td>PAT Margins</td><td>%</td><td>-6%</td><td>-</td></tr><tr><td>Debt Equity</td><td>Times</td><td>0.1</td><td>-</td></tr><tr><td>Return on Equity</td><td>%</td><td>-6%</td><td>-</td></tr><tr><td>Return on Assets</td><td>%</td><td>-4%</td><td>-</td></tr><tr><td>Return on Capital Employed</td><td>%</td><td>-0%</td><td>-</td></tr></tbody></table>

Source: Company Reports

Note: Since, the EBIT is negative for the FY23, Capital employed is reflecting negative

## ➤ Molbio Diagnostics Pvt Ltd,

Molbio Diagnostics Pvt Ltd, specializes in molecular diagnostics, focusing on diseases like tuberculosis, COVID-19, and HIV. The company manufactures Truenat test kits, which enable point-of-care molecular testing, providing rapid and accurate results. With a production capacity of 3.5 lakh units per day by a new manufacturing unit in Goa, Molbio serves a global market with high demand for the diagnostic solutions. The company is dedicated to making molecular testing more accessible, particularly in resource-limited areas, and has improving their diagnostics system for infectious diseases, especially tuberculosis.

<table><thead><tr><th></th><th>Unit</th><th>FY23</th><th>FY24</th></tr></thead><tbody><tr><td>Revenue</td><td>Rs. Million</td><td>3,325</td><td>-</td></tr><tr><td>Revenue Growth</td><td>%</td><td>-</td><td>-</td></tr><tr><td>Operating Profit</td><td>Rs. Million</td><td>432</td><td>-</td></tr><tr><td>Operating Margins</td><td>%</td><td>13%</td><td>-</td></tr><tr><td>PAT</td><td>Rs Million</td><td>-34</td><td>-</td></tr><tr><td>PAT Margins</td><td>%</td><td>-1%</td><td>-</td></tr><tr><td>Debt to Equity</td><td>Times</td><td>0.1</td><td>-</td></tr><tr><td>Return on Equity</td><td>%</td><td>-0%</td><td>-</td></tr><tr><td>Return on Assets</td><td>%</td><td>-0%</td><td>-</td></tr><tr><td>Return on Capital Employed</td><td>%</td><td>2%</td><td>-</td></tr></tbody></table>

Source: Company Reports

## ➤ Agappe Diagnostics

Agappe Diagnostics produces reagents for diagnostic testing and immunoassay kits for various diseases, including infections and chronic conditions. Agappe's Diagnostics production capacity includes 120,000 kits per shift per month and 1,250 pieces of equipment per shift per month. The company places an emphasis on R&D and manufacturing excellence. Agappe Diagnostics provides affordable diagnostic solutions in both domestic and international markets.

<table><thead><tr><th></th><th>Unit</th><th>FY23</th><th>FY24</th></tr></thead><tbody><tr><td>Revenue</td><td>Rs. Million</td><td>3,905</td><td>4426</td></tr><tr><td>Revenue Growth</td><td>%</td><td>-</td><td>13%</td></tr><tr><td>Operating Profit</td><td>Rs. Million</td><td>439</td><td>413</td></tr><tr><td>Operating Margins</td><td>%</td><td>11%</td><td>9%</td></tr><tr><td>PAT</td><td>Rs Million</td><td>235</td><td>174</td></tr><tr><td>PAT Margins</td><td>%</td><td>6%</td><td>4%</td></tr><tr><td>Debt to Equity</td><td>Times</td><td>0.2</td><td>0.2</td></tr><tr><td>Return on Equity</td><td>%</td><td>10%</td><td>7%</td></tr><tr><td>Return on Assets</td><td>%</td><td>6%</td><td>4%</td></tr><tr><td>Return on Capital Employed</td><td>%</td><td>13%</td><td>10%</td></tr></tbody></table>

Source: Company Reports